Generic placeholder image

Current Drug Targets - CNS & Neurological Disorders


ISSN (Print): 1568-007X
ISSN (Online): 1568-007X

Therapeutic Potential of 5-HT2C Receptor Antagonists in the Treatment of Anxiety Disorders

Author(s): Martyn D. Wood

Volume 2, Issue 6, 2003

Page: [383 - 387] Pages: 5

DOI: 10.2174/1568007033482698

Price: $65


Anxiety disorders are the most common psychiatric illness affecting both adults and children. Following the observation that m-chlorophenylpiperazine(mCPP) induced anxiety-like states in patients and in animal models, it was shown that in man, mCPP behaves as a functionally selective agonist at the 5-hydroxytryptamine (5-HT)2C receptor. This caused much interest in the development of antagonists at the 5-HT2C receptor for the treatment of anxiety disorders. This review examines the pre-clinical and clinical evidence for a role of the 5-HT2C receptor in anxiety and evaluates the progress of compounds that target this therapeutic approach.

Keywords: 5-hydroxytryptamine, 5-ht, anxiety, antagonists

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy